Case Reports Epublish 2 citations
PubMed: 37736932 DOI: 10.3390/clinpract13050096
Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
Clin Pract 13(5):1082-1089
Authors: Alexander Yakobson, Ala Eddin Neime, Omar Abu Saleh, Kayed Al Athamen, Walid Shalata
Affiliations
- The Legacy Heritage Cancer Center and Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel.
- Department of Internal Medicine, Soroka Medical Center & Ben-Gurion University, Beer Sheva 84105, Israel.
- Dermatology and Venereology, The Emek Medical Centre, Afula 18341, Israel.
Abstract
Advancements and the use of tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of Chronic Myeloid Leukemia (CML), achieving unprecedented success rates and expanding their applications to various neoplasms. However, the use of TKIs is not without its drawbacks. Skin, gastrointestinal, and central nervous systems are particularly susceptible to adverse effects, including a higher incidence of autoimmune responses in treated individuals. In this report, we present a unique case of bullous pemphigoid, a rare autoimmune disease, which has not been previously associated with TKI therapy as an adverse effect, particularly appearing after discontinuing Imatinib treatment.
MeSH
Therapeutics, Pemphigoid, Bullous